Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Hiroyuki M. Tanaka

Organization For Promotion Of Tenure Track, 
Miyazaki, JP 
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Organization For Promotion Of Tenure Track, 
Miyazaki, JP 
OverviewLocationsClinical Research

Overview

Hiroyuki Tanaka practices in Miyazaki, Japan. Mr. Tanaka is rated as an Experienced expert by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Coronary Artery Aneurysm, X-Linked Hypophosphatemia, Hypophosphatemia, Angioplasty, and Percutaneous Coronary Intervention (PCI).

His clinical research consists of co-authoring 983 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Gender
Male

Locations

Organization For Promotion Of Tenure Track, Miyazaki, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 3
A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency
A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

983 Total Publications

Phage lysis protein LysM acts as a wedge to block MurJ conformational changes.
Phage lysis protein LysM acts as a wedge to block MurJ conformational changes.
Journal: Science advances
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tanaka's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 32 Advanced Conditions
View All 283 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile